Cardio MedBed: A Breakthrough for Ocular Ischemic Diseases
Important: This article is intended for educational purposes only. Patients should always talk to their doctor before trying any new treatment.
Ocular ischemic diseases are serious conditions caused by reduced blood flow to the eyes, often resulting in vision loss. Treatment options remain limited. However, research highlights the potential of Enhanced External Counterpulsation (EECP), also marketed as the "Cardio MedBed," in improving blood flow to the eyes.
This article examines the potential of EECP in enhancing outcomes for patients with ocular ischemic diseases, although results have been mixed.
1. Improvement in Visual Acuity and Hemodynamics (June 2013)
A study published in Molecular Medicine Reports in June 2013 investigated EECP effects on 65 patients with ocular ischemic conditions. Researchers compared EECP plus drugs versus drugs alone.
Key Findings:
Improved Visual Acuity: Patients in the EECP group experienced a significant enhancement in their ability to see clearly.
Better Visual Fields: The therapy expanded patients' visual fields, allowing them to see a broader range.
Enhanced Optical Blood Flow: Improved blood flow in the eyes was observed, which helps restore oxygen and nutrients for optimal visual function.
These results suggest EECP may help address vision impairment in ocular ischemic diseases when combined with other treatments.
2. A Safe and Effective Treatment for NAION (January 2015)
A study published in Graefe's Archive in January 2015 evaluated EECP's effects in treating non-arteritic anterior ischemic optic neuropathy (NAION), a condition caused by poor blood supply to the optic nerve. The study treated 16 patients with 12 daily EECP sessions.
Key Findings:
Improved Blood Flow: EECP increased blood flow velocities in the eye arteries and decreased eye pressure.
Better Visual Outcomes: Visual acuity improved, and visual field defects decreased after treatment.
Non-Invasive Approach: EECP provides a non-invasive alternative that supports circulation enhancement.
The authors concluded EECP could be clinically effective and safe for NAION.
Conclusion: Pioneering a New Standard in Eye Care
EECP shows promise as a therapeutic option for ocular ischemic diseases, based on preliminary research. However, evidence remains limited, particularly for NAION treatment.
Patients should understand that evidence is still developing.
Patient Advice: Talk to eye doctors about all treatment options before considering EECP for vision problems.